Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Business & Profession Professional Development

Business in Brief

  • Novartis CEO Joe Jiminez had previously imposed an end-of-year deadline for Alcon to halt falling sales – suggesting that it might end up for sale. Rumors were flamed at an M&A conference in Zurich on Thursday, General Counsel Felix Ehrat would not rule out a sale of Alcon, and is quoted as saying, “Never say never.”
  • The FTC state that Valeant has agreed to sell Paragon Holdings Inc. to restore competition in the gas-permeable contact lens market. The agreement has come following allegations that Valeant’s acquisition of the company in 2015 was illegal under antitrust law.
  • US prosecutors brought corporate fraud and money laundering charges against Andrew Davenport, a former head of Valeant’s mail 0rder pharmacy unit, Philidor Rx Services, as well as former Valeant manager, Gary Tanner, claiming that Valeant has been defrauded by a secret Philidor kickback scheme.
  • Allergan’s XEN glaucoma treatment system has received FDA clearance and will be available for use in the US in early 2017.
  • Stealth BioTherapeutics has announced its commencement of a Phase I study to evaluate safety and tolerability of its mitochondrial-targeting drug elamipretide in patients (aged 55 years or older) with dry AMD. Topline results are anticipated in mid-2017.
  • Regeneron has announced a revenue increase of seven percent compared with the same quarter of last year, with net sales of aflibercept increasing by 16 percent.
  • Carl Zeiss’ Chief Executive, Michael Kaschke told the German newspaper Welt Am Sonntag that the company is looking for targeted takeovers to boost the group’s expansion.
  • Allegro Ophthalmics has announced that William Link – co-founder and managing director of Versant Ventures – has joined their board of directors.
Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register